The World Health Organization (WHO) has recommended prioritizing three experimental treatments against the Bundibugyo strain of Ebola virus, including MBP134 from Mapp Biopharmaceutical, maftivimab from Regeneron, and the antiviral remdesivir from Gilead Sciences, the latter also used during the Covid-19 pandemic, Reuters reports.